CORAL SPRINGS, Fla., March 14, 2012 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that has developed treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged LWR Partners, an outside branding and marketing firm to aid in the promotion, branding and distribution of Nyloxin.
"We are excited to be working with LWR Partners to begin our first real marketing efforts for Nyloxin," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "While the Nyloxin products have been available for over a year, sales have been slow as the Company has depended on third-party sales and distributors to get the word out. We are now starting a campaign to have a unified brand strategy and appropriate marketing in our attempt to move sales up consistently both in the United States and abroad," he concluded.
Nyloxin is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
"The Nyloxin products represent a wonderful marketing opportunity," commented James Warble, CEO of LWR Partners. "These are pain-relievers and anti-inflammatory drugs that have provided great results with almost no risk of side effects. The only thing missing is a branding and marketing strategy to let the world know about the power of these products," he continued. "LWR will begin an aggressive campaign of digital marketing that includes audio, video, social media, internet banners and sales through more than 10,000 affiliated websites. This will allow the opportunity for sustainable sales growth while building a uniform branding strategy for the products," he concluded.
LWR Partners / "Brands To Market" are a select team of best-in-class experts in branding, advertising and media deployment, with a passion for entrepreneurial brand stewardship that knows how to maximize the value of a company's brand. As a next generation Digital Media Deployment Provider, LWR connects brands to customers through a suite of digital products that includes SMS Mobile, Email, Social Media, Online Video, Web Advertising and Point of Decision media. LWR Partners have created and guided traditional brands like The Die Hard Battery, Taster's Choice Coffee, Jimmy Dean Sausage and currently works with ABA Basketball, The "Seeds of Freedom" Foundation, Commerce Science Corporation and many new top quality Brands. The company is headquartered in Boca Raton, Florida with offices in Atlanta, Nashville, Scottsdale, Austin, Salt Lake City, Scranton, PA and Princeton, NJ
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The engagement of LWR Partners should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
SOURCE Nutra Pharma Corporation